Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Completed · Phase 3 · Has a placebo group

Conditions studied: Osteoporosis

In brief

The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine and total hip

Key facts

Study ID

NCT00439244

Run by

Novartis

People needed

412

Starts

2006-12-01

Expected to finish

2009-02-01

Last updated by the study team

2011-04-20

Who can join

Age: 45 and older, up to 89. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal (PMO) women between 45 and 89 years of age.
• Bone mineral density T score of -2.5 or less at femoral neck, total hip or lumbar spine OR
• Bone mineral density T score of -2.0 or less at femoral neck, total hip or lumbar spine with at least one documented osteoporotic vertebral fracture or a previously documented history of an osteoporotic clinical non-vertebral fracture not due to excessive trauma

You may not qualify if…

• Any prior use of strontium
• Any past or active kidney disease or problems with kidney function
• Prior treatment with any intravenous (i.v.) or oral bisphosphonate (such as but not limited to alendronate, risedronate and pamidronate) longer than 3 months consecutively. If bisphosphonate exposure is less than or equal to 3 months , a washout period of 1 year to randomization is required
• Calcium levels in blood within the normal range
• Normal liver function
• Non-osteoporotic forms of metabolic bone disease such as and not limited to Paget's disease of bone, osteomalacia, osteogenesis imperfecta or multiple myeloma
• Less than 3 evaluable lumbar (L1-L4) vertebrae for dual energy x-ray absorptiometry (DXA) measurement
• Treatment with osteoporotic therapies such as raloxifene, calcitonin or Hormone Replacement Therapy within 3 months of randomization
• Allergy or previous exposure to teriparatide
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Beverly Hills, California, United States
• Novartis Investigative Site — La Mesa, California, United States
• Novartis Investigative Site — Oakland, California, United States
• Study site — Colorado Springs, Colorado, United States
• Study site — Lakewood, Colorado, United States
• Study site — Gainesville, Georgia, United States
• Study site — Morton Grove, Illinois, United States
• Study site — Urbandale, Iowa, United States
• Study site — Bangor, Maine, United States
• Novartis Investigative Site — Woodbury, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — Lincoln, Nebraska, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — West Haverstraw, New York, United States
• Novartis Investigative Site — Pittsburgh, Pennsylvania, United States
• Novartis Investigative Site — Spokane, Washington, United States
• Study site — Madison, Wisconsin, United States
• Novartis Investigative Site — Brussels, Belgium
• Novartis Investigative Site — Ghent, Belgium
• Novartis Investigative site — Godinne, Belgium
• Novartis Investigative Site — Leuven, Belgium
• Novartis Investigative Site — Liège, Belgium
• Novartis Investigative Site — Essen, Germany
• Novartis Investigative Site — Hanover, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.